Emergence of Cytotoxic T Lymphocyte Escape Mutants following Antiretroviral Treatment Suspension in Rhesus Macaques Infected with SIVmac251  by Nacsa, Janos et al.
Emergence of Cytotoxic T Lymphocyte Escape Mutants following Antiretroviral Treatment
Suspension in Rhesus Macaques Infected with SIVmac251
Janos Nacsa,* Jennifer Stanton,† Kevin J. Kunstman,† Wen-Po Tsai,* David I. Watkins,‡
Steven M. Wolinsky,† and Genoveffa Franchini*,1
*National Cancer Institute, Basic Research Laboratory, 41/D804, Bethesda, Maryland 20892; †Northwestern University Medical School,
Division of Infectious Diseases, Tarry 3-735, 303 East Chicago, Chicago, Illinois 60611; and ‡Wisconsin Regional Primate
Research Center, 1220 Capitol Court, Madison, Wisconsin 53715
Received June 14, 2002; returned to author for revision August 22, 2002; accepted August 30, 2002
Structured treatment interruption (STI) of antiretroviral drugs has been proposed as an alternative approach for managing
patients infected with HIV-1. While STI is thought to spare drug-related side effects and enhance the HIV-1-specific immune
response, the long-lasting clinical benefit of this approach remains uncertain, particularly in patients with long-standing HIV-1
infection. Here, we investigated the basis of unabated virological replication following different STI regimens in rhesus
macaques that expressed the MHC class I Mamu-A*01 molecule treated during acute and long-standing infection with
SIVmac251. An amino acid change at the anchor residue within the immunodominant Mamu-A*01-restricted Gag181–189 CM9
epitope (T 3 A) in one of six macaques with acute SIVmac251 infection and in three of four macaques with long-standing
SIVmac251 infection (T3 A; T3 S; S3 C) was found in the majority of plasma virus. These amino acid changes have been
shown to severely decrease binding of the corresponding peptides to the Mamu-A*01 molecule and, in the case of the T3
A change, escape from CTL. In one macaque with long-standing SIVmac251 infection, a mutation emerged that conferred
resistance to one of the antiretroviral drugs (PMPA) as well. These results provide insights into the mechanism underlying
the limited capacity of repeated interruption of antiretroviral therapy as an approach to restrain viral replication. In addition,escape and that immune escape is a risk of interruption o
INTRODUCTION
Potent antiretroviral therapy can control infection with
HIV-1 in many patients by reducing the extent of ongoing
viral replication in CD4 T cells and other cell types in
blood and lymphoid tissue. This reduction in HIV-1 rep-
lication associates with improved immune function (Au-
tran et al., 1997) and decreased patient morbidity and
mortality (Palella et al., 1998). Although combinations of
antiretroviral drugs can suppress replication of HIV-1 for
a long time, a long-lived reservoir of infectious virus
remains (Chun et al., 1997; Finzi et al., 1999; Furtado et
al., 1999; Wong et al., 1997), indicating the need for
lasting treatment. The continued presence of this reser-
voir of HIV-1 represents a likely impediment to the en-
during control of viral infection.
Structured treatment interruption (STI) of potent anti-
retroviral drug therapy has been explored as an alterna-
tive approach to manage patients with HIV-1 infection
(Davey et al., 1999; Lisziewicz et al., 1999; Lori and
Lisziewicz, 2001) that would enhance the HIV-1-specific
immune response (Ortiz et al., 1999) and reduce drug-0042-6822/02 $35.00
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related toxicity. STI begun during early infection with
HIV-1 may preserve the HIV-1-specific CD4 and CD8 T
cell response and maintain immune control (Berrey et al.,
2001; Markowitz et al., 1999; Rosenberg et al., 2000;
Spiegel et al., 2000), whereas later initiation of STI may
resurrect a dormant HIV-1-specific CD8 T cell response
(Davey et al., 1999; Ortiz et al., 1999). A clinical benefit of
this approach is likely limited to those patients who start
STI soon after their infection with HIV-1, however, an
observation supported by the rhesus macaque model of
AIDS (Hel et al., 2000; Lifson et al., 2000; Lori et al., 2000;
Mori et al., 2000).
Despite evidence that STI can contain ongoing viral
replication and preserve or augment the immune re-
sponse in selected people in the early stage of HIV-1
infection (Berrey et al., 2001; Hel et al., 2000; Markowitz
et al., 1999; Montefiori et al., 2001; Rosenberg et al.,
2000), the fundamental mechanism underpinning the ob-
served clinical benefits for these particular persons is
unknown. In addition, it is not known to what extent
failure of this approach represents virus escape from
immune control, especially in the setting of increased
antigenic variation and waned immunity found during
long-standing HIV-1 infection (Casazza et al., 2001; Graythese data also suggest that interruption of therapy may be
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et al., 1999; Ogg et al., 1999). Therefore, we used the
rhesus macaque model of AIDS to assess the underlyingless ef
f therap
mechanisms of virological failure after STI in macaques
with the Mamu-A*01 haplotype that had had acute and
long-standing infection with SIVmac251.
RESULTS
Viral rebound in plasma in macaques treated with
ART during primary infection with SIVmac251
Six rhesus macaques were treated with the combina-
tion of DDI, d4T, and PMPA 15 days after an intravenous
inoculation with SIVmac251. IL-2 was administered to-
gether with antiretroviral drug therapy. Before interrup-
tion of antiretroviral drug therapy, plasma levels of SIV
RNA remained below the detectable limit. The details on
the immunological response in these animals is reported
elsewhere (J. Nacsa, Z. Hel, W.-P. Tsai, E. Tryniszewska,
L. Giuliani, J. Altman, M. G. Lewis, P. Markham, D. Ven-
zon, N. Bischofberger, S. M. Wolinsky, J. Tartaglia, K. A.
Smith, and G. Franchini, unpublished data).
After interruption of antiretroviral drug therapy, the
increase in the level of SIV RNA in plasma in three
animals (macaques 683, 686, 706) occurred during the
administration of IL-2 and was transient (Fig. 1A). After
IL-2 suspension, two of these animals (macaques 686
and 706) had subsequent transient increases in plasma
SIV RNA, whereas one macaque (animal 683) had a
substantial increase in the level of SIV RNA in plasma
associated with rapid progression to SIV disease and
death (Fig. 1A). Three other animals (macaques 685, 680,
760) had a transient upsurge in the concentration of SIV
RNA in plasma 10 to 20 days after the cessation of IL-2
treatment (Fig. 1B). All three of these macaques subse-
quently maintained levels of plasma SIV RNA below 2000
copies per 100 l of plasma without antiretroviral drug
treatment.
SIVmac Gag-specific CD8 T cells in macaques
treated during acute infection
We next sought an association between the rise and
fall in the level of plasma viral RNA after STI and the
expansion of SIV-specific CD8 T cells. Staining of CD3
CD8 T cells of blood in rhesus macaques with (ma-
caques 680, 683, 685, 686, and 706) and without (ma-
caque 760) the Mamu-A*01 haplotype with the Mamu-
A*01-restricted SIV Gag181–189 CM9 tetramer (Allen et al.,
1998; Kuroda et al., 1998) revealed an expansion of the
SIV-specific CD8 T cell population (up to 16%) in ma-
caques 683, 686, and 706 that was associated with a 2
log fall in the level of plasma SIV RNA following the
suspension of antiretroviral drug therapy (Fig. 1A). The
increased frequency of SIV-specific CD8 T cells in pe-
ripheral blood in macaque 680 was found in the absence
of detectable viral RNA in plasma (Fig. 1B). As expected,
the PBMC of the Mamu-A*01-negative macaque 760 did
not stain with the Gag181–189 CM9 tetramer (Fig. 1B). Ma-
caque 683 had an abrupt rise in the level of SIV RNA in
plasma, despite the highest frequency (16%) of SIV-spe-
cific CD8 T cells (Fig. 1A).
To determine the association of the loss of immune
control with the appearance of nonsynonymous substi-
tutions in the amino acid residues that likely affect bind-
ing to the MHC class I molecule Mamu-A*01, we as-
sessed the extent of genetic diversity within the Mamu-
A*01-restricted Gag181–189 CM9 epitope over time. We
used DNA sequencing of PCR-product DNA amplified
from plasma viral RNA at end-point dilution to assess the
frequency of mutations coding for amino acid changes in
the Mamu-A*01-restricted Gag181–189 CM9 epitope in the
SIV gag gene.
DNA sequence analysis of the SIVmac251 viral stock
used to infect all macaques studied here (Pal et al., 2001)
showed the inferred wild-type Mamu-A*01-restricted
Gag181–189 CM9 epitope sequence (CTPYDINQM) in 42 of
42 independent Gag clones (data not shown). The de-
duced amino acid sequence of the Mamu-A*01-re-
stricted Gag181–189 CM9 epitope was determined for up to
11 independent clones from viral RNA in plasma begin-
ning at day 15 of viral inoculation and thereafter for
macaques with primary SIV infection, as indicated by
arrows in Figs. 1A and 1B.
For macaque 683, few amino acid changes were ob-
served in the Gag181–189 CM9 epitope at the time of pri-
mary infection with SIVmac251 (day 15), as well as at the
first and second resurgences of virus (days 168 and 210)
(Fig. 1C). By day 238, however, the T3 A substitution in
the second amino acid position of the Mamu-A*01-re-
stricted Gag181–189 CM9 epitope emerged in the plasma
virus (Fig. 1C). In macaque 683, the appearance of this
particular substitution was associated with a rapid rise in
the level of plasma SIV RNA, progression of disease, and
death due to an AIDS related illness. The T3 A change
at position 2 of the Gag181–189 CM9 peptide reduces its
binding capacity to the Mamu-A*01 molecule (Sidney et
al., 2000), thereby affecting presentation by the Mamu-
A*01 molecule and CTL recognition (Chen et al., 2000). In
contrast, the viral plasma RNA from macaques 680, 706,
and 686 carried the predominant CTPYDINQM sequence
of epitope Gag181–189 CM9 in the virus challenge stock
throughout the time of analysis (Figs. 1A–1C).
Viral rebound in plasma in ART-treated macaques
with long-standing infection with SIVmac251
The combination of DDI, d4T, and PMPA with or with-
out low dose of IL-2 was given for 5 months to four
macaques infected with SIVmac251 for 11 months or
more. Table 1 shows the level of SIV RNA in plasma
(range, 8.8  105 to 9.2  106 copies per ml) and CD4
T cell number in peripheral blood (range, 449 to 1415
cells per ml) before the start of treatment. Macaques 432
and 449 had previously received ALVAC-SIV-gag-pol-env
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FIG. 1. Kinetics of virus-specific CD8 T cell responses, plasma virus resurgence, and viral immune escape following STI in macaques treated in primary
infection. A and B: Six macaques were infected by the intravenous route with SIVmac251. All animals became viremic and were treated with ART at day 15
from exposure to SIVmac251 (561) (Pal et al., 2001). These animals were treated with ART for 154 days and initiated on low-dose IL-2 treatment at day 70
and maintained until day 196. At day 196, all treatment was suspended. Macaques 683, 686, 685, and 760 were also vaccinated with NYVAC-SIV-gpe (J.
Nacsa, Z. Hel, W.-P. Tsai, E. Tryniszewska, L. Giuliani, J. Altman, M. G. Lewis, P. Markham, D. Venzon, N. Bischofberger, S. M. Wolinsky, J. Tartaglia, K. A. Smith,
and G. Franchini, unpublished data), whereas the remaining macaques were mock-vaccinated with NYVAC. Data from these macaques in which viral
rebound was detected following weekly assessment of viremia are presented in Figs. 1A and 1B.  represents the level of viremia overt time. F represents
frequency of CD3 CD8 Gag181–189 CM9-specific T cells in blood. *refers to the Mamu-A*01-negative macaque (760) whose blood was used as a control
for the specificity of tetramer staining. The arrows indicate the time of analysis of plasma RNA for the data presented in Fig. 1C. C: A single letter amino
acid code of the presumed amino acid sequence of the Gag181–189 CM9 epitope over time in plasma of macaques 683, 706, and 686.
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(ALVAC-SIV-gpe) (Pal et al., 2001); macaque 644 had
received NYVAC-SIV-gag-pol-env (NYVAC-SIV-gpe), and
macaque 642 had received NYVAC alone (Hel et al.,
2000) and had sustained elevation in the concentration
of SIV RNA in plasma for 11 months or more. During
treatment with a potent combination of antiretroviral
drugs augmented by low-dose IL-2, plasma levels of SIV
RNA remained below detectable level. Cyclic interrup-
tions of antiretroviral therapy were begun with (ma-
caques 432 and 642) and without (macaques 449 and
644) overlapping IL-2 administration.
The level of SIV RNA in plasma in macaques 449 and
644 rose substantially (105 copies per ml) after the first
interruption of antiretroviral drug therapy and remained
high thereafter, despite reinstitution of treatment (Fig.
2A). Macaque 449 developed clinical SIVmac disease
progression and was euthanized because of AIDS-re-
lated complications. Likewise, the concentration of
plasma SIV RNA in macaques 432 and 642 rose (104
copies per ml) and then fell below the threshold in the
interval between the beginning and end of the first STI.
All four of these macaques subsequently maintained
levels of plasma SIV RNA above 5  104 copies per
milliliter without antiretroviral drug treatment (Fig. 2A).
Before the interruption of treatment, we found no muta-
tion coding for resistance to DDI, d4T, and PMPA in the
reverse transcriptase gene of plasma viral RNA. After the
first interruption of antiretroviral drug therapy, a mutation
coding for resistance to PMPA (K65R) (Van Rompay et al.,
1996) was found in the plasma virus reverse transcrip-
tase gene of monkey 644, which associated with the
burst of viral replication, loss of CD4 T cells, and pro-
gression to SIVmac disease. No drug-resistant mutations
were found in the plasma viral RNA from the other rhesus
macaques, indicating that STI did not usually select for
drug resistance.
SIVmac Gag-specific CD8 T cells in macaques after
long-standing infection with SIVmac251
SIV-specific CD8 T cells staining with the immuno-
dominant Mamu-A*01-restricted SIV Gag181–189 CM9 tet-
ramer related to the presence or absence of concurrent
IL-2 administration. Before starting antiretroviral drug
therapy, the frequency of CD8 T cells stained with the
Mamu-A*01 peptide tetrameric complex for the major
Mamu-A*01-restricted SIV Gag181–189 CM9 in all four ma-
caques ranged from 0.25 to 1.5% (Fig. 2B). In the absence
of IL-2 (macaques 449 and 644), there was no change in
the frequency of SIV-specific CD8 T cells staining with
this Mamu-A*01 tetrameric molecule (Fig. 2A). In the
presence of IL-2 (macaques 432 and 642), the frequency
of SIV-specific CD8 T cells staining with the Mamu-
A*01-restricted SIV Gag181–189 CM9 tetramer was high,
especially in macaque 432 (up to 40%) (Fig. 2A).
We assessed the genetic variation within the Mamu-
A*01-restricted Gag181–189 CM9 epitope by screening for
mutations that accrued in amino acid residues critical for
this epitope presentation (Sidney et al., 2000). Amino
acid substitutions were principally limited to the anchor
residue in the second position of this Mamu-A*01-re-
stricted Gag181–189 CM9 epitope sequence as deduced
T 3 A, T 3 S, and S 3 C (macaque 644) substitutions
that existed before or emerged immediately after the
interruption of treatment (Fig. 2C). In macaque 432, 26
days after stopping antiretroviral drug therapy, a T 3 A
substitution emerged in the second position of the
Mamu-A*01-restricted Gag181–189 CM9 epitope (Fig. 2C). In
macaque 449, only 1 of the 10 clones obtained at the
start of treatment (day 0) had the canonical Gag181–189
CM9 epitope sequence. By the time of the first interrup-
tion of antiretroviral treatment, the T 3 A substitution
became the predominant Gag181–189 CM9 epitope in virus
in plasma (Figs. 2B, top panel, and 2C). Each of the
amino acid changes in the second position of CTPY-
DINQM has been shown to decrease or abrogate the
binding capacity of the Gag181–189 CM9 peptide to the
Mamu-A*01 molecule (Sidney et al., 2000).
DISCUSSION
In patients infected with HIV-1, long-lived reservoirs of
infectious virus persist (Chun et al., 1997; Finzi et al.,
1999; Furtado et al., 1999; Wong et al., 1997) despite
TABLE 1
Previous History, Virus Load, and CD4 T Cell Count in Mamu-A*01-Positive Macaques with Long-Standing SIVmac251 Infection
Treatment ART ART  IL-2
Animal Viral copies/ml of
plasma/viremic
span (months)
CD4 T cells at start
of ART
Animal Viral copies/ml of
plasma/viremic
span (months)
CD4 T cells at start
of ART
449a 1.5 106/11 523 432a 8.3 105/15 597
644b 3.1106/5 367 642c 9.2 106/12 1415
a Previously vaccinated with ALVAC-SIV-gpe (Pal et al., 2001).
b Previously vaccinated with NYVAC-SIV-gpe (Hel et al., 2000).
c Previously mock-vaccinated with NYVAC (Hel et al., 2000).
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treatment with combinations of antiretroviral drugs that
suppress ongoing viral replication and reduce plasma
viral RNA to undetectable levels. The persistent pres-
ence of reservoirs of HIV-1 has been the impetus for
exploring alternative treatment strategies, including STI
as a means to reduce drug-related toxicity and enhance
the HIV-1-specific immune response (Davey et al., 1999;
Lisziewicz et al., 1999; Ortiz et al., 1999). Clinical experi-
FIG. 2. Kinetics of virus-specific CD8 T cell response, plasma virus resurgence, and viral immune escape in macaques with long-standing
SIVmac251 infection. A: Level of plasma viremia over time () and frequency (F) of Gag181–189 CM9 tetramer-positive CD3 CD8 T cells during STI
and after IL-2 suspension in four Mamu-A*01-positive macaques. B: Percentage of Gag181–189 CM9 tetramer-positive CD3
 CD8 T cells in the blood
of the four Mamu-A*01-positive macaques at the start of treatment. C: Analysis of the genetic composition of plasma virus with respect to the amino
acid sequence of peptide Gag181–189 CM9 over time in macaques 449, 644, 642, and 432. A single letter amino acid code of the presumed amino acid
sequence of the Gag181–189 CM9 epitope is presented. The number 0 refers to initiation of ART. The initiation of ART with respect to the time from
infection for these macaques is summarized in Table 1.
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ence with each of these alternative approaches to the
immune control of viral replication has been less than
satisfactory, especially in patients with long-standing
HIV-1 infection.
Here we investigated the basis of unabated virological
failure in rhesus macaques that expressed the MHC
class I molecule Mamu-A*01 through a course of STI
during acute and long-standing infection with SIV-
mac251. We measured the frequency of SIV-specific
CD8 T cells staining with the Mamu-A*01-restricted SIV
Gag181–189 CM9 tetramer (Allen et al., 1998; Kuroda et al.,
1998) and tracked changes in the targeted immunodom-
inant Gag181–189 CM9 epitope over time. Certain rhesus
macaques received concurrent low-dose IL-2 as a
means to overcome defects in IL-2 production demon-
strated previously for people infected with HIV-1 (Allen et
al., 1998; Allouche et al., 1990; Nicastri et al., 1999; Pal et
al., 2001; Sidney et al., 2000; Westby et al., 1998). We
found that five of six macaques with acute infection with
SIVmac251 had had transient increases in the level of
SIV RNA in plasma (up to 105 copies per ml) and an
expansion of the frequency of SIV-specific CTL after the
interruption of antiretroviral drug therapy. One macaque
(683) had had a significant increase in the level of SIV
RNA in plasma (107 copies per ml) with a rapid pro-
gression to SIV disease and death from AIDS-related
complications. It is uncertain whether the mutation in the
Gag181–189 CM9 epitope resulted in high viremia or
whether the high viremia resulted in selection of this
mutant virus. However, it seems reasonable to hypothe-
size that escape to this dominant response may be an
underlying cause of uncontrolled viral replication, as
demonstrated also by others (Barouch et al., 2002).
All four macaques with long-standing infection with
SIVmac251 had had substantial increases in plasma viral
RNA (105 copies per ml) after the first interruption of
antiretroviral drug therapy that persisted despite a sec-
ond cycle of STI. Measurable SIV-specific CD8 T cells
staining with the Mamu-A*01-restricted SIV Gag181–189
CM9 tetramer were found in the two macaques that
received IL-2 as well. All four of these macaques had
preexisting or developed nonsynonymous substitutions
in the second position of the Mamu-A*01-restricted SIV
Gag181–189 CM9 epitope that affect binding to the cognate
MHC class I molecule (Sidney et al., 2000). One monkey
had plasma SIV RNA with a mutation that conferred
PMPA resistance.
In the rhesus macaque model for AIDS, antiretroviral
therapy alone given during the early stage of infection
has long-term clinical benefit in most cases (Franchini,
2002; Hel et al., 2000; Lifson et al., 2000; Lori et al., 2000;
Mori et al., 2000), suggesting that early treatment gives
the immune system the opportunity to establish some
measure of long-term control of viral replication, perhaps
by avoiding viral escape from epitopes with high avidity
(O’Connor et al., 2002). In rhesus macaques with long-
standing infection with SIVmac251, however, this ap-
proach did not appear to provide the same advantage,
likely because viral escape to high-avidity CTL epitopes
has already occurred in most cases, as demonstrated by
others (O’Connor et al., 2002) and our work here, since
we already observed changes in the Gag181–189 CM9
epitope in two of the four chronically infected macaques
at the beginning of the study. Thus, the clinical benefit of
STI may be restricted to those patients infected with
HIV-1 who present early in the course of their disease.
The failure of STI to contain viral replication in macaques
with primary and long-standing infection with SIVmac251
was associated with evolution and emergence of viral
escape from immune recognition. All the amino acid
changes that we found in the second position of the
immunodominant Gag181–189 CM9 epitope in the four ma-
caques decreased the binding capacity of the corre-
sponding peptides to the MHC class I Mamu-A*01 mol-
ecule (Sidney et al., 2000) and in the case of the T 3 A
also escape from CTL has been clearly demonstrated
(Chen et al., 2000). Thus, escape from this dominant
response may contribute to disease progression as also
observed previously in one animal infected with
SHIV89.6P (Barouch et al., 2002). Unlike virus escape
from antiretroviral drug treatment brought about by con-
stant selection pressure on the virus population, virus
escape from immune control changes the selection pres-
sure applied by the immune system. In the setting of
long-term infection with SIVmac, STI may drive this pro-
cess further and therefore precipitate the changes that
allow the virus to escape from CTL.
Taken together, these data suggest that controlled
interruptions of antiretroviral therapy may contribute to
the selection of viral immune escape in both primary and
long-standing infection. The extent of virus diversity and
evolution (Wolinsky et al., 1996), particularly during
chronic infection, functional impairment of virus-specific
CD8 T cells (Appay et al., 2000; Goepfert et al., 2000;
Hel et al., 2001; Kostense et al., 2001; Shankar et al.,
2000; Vogel et al., 2001; Westby et al., 1998), and lack of
adequate CD4 T cell help (Rosenberg et al., 1997; Vil-
linger et al., 2002), are all potential additional underlying
mechanisms. Caution is therefore warranted when con-
sidering STI as a therapeutic approach in HIV-1-infected
individuals. Perhaps strengthening the host immune re-
sponse by vaccination before STI may result in contain-




All macaques were colony-bred rhesus macaques
(Macaca mulatta) housed and handled in accordance
with the standards of the American Association for the
Accreditation of Laboratory Animal Care. No macaque
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had confirmed STLV-1 or herpesvirus B infection before
entering the study. MHC class I haplotype restriction was
determined by a high-resolution molecular typing assay
as described previously (Knapp et al., 1997). Macaques
were inoculated with the same stock of pathogenic SIV-
mac251 (561) (Pal et al., 2001). All macaques received a
triple-drug antiviral regimen that included the intrave-
nous administration of DDI (10 mg/kg) once a day, oral
administration of d4T (1.2 mg/kg/dose) twice a day, and
subcutaneous administration of PMPA (20 mg/kg) once a
day as previously described (Hel et al., 2000).
Six treatment-naive rhesus macaques were infected
with SIVmac251 (day 0) and then treated with the triple-
drug antiviral regimen 15 days later. Four of these ma-
caques were also vaccinated with NYVAC-SIV-gpe (Ben-
son et al., 1998) (Fig. 1, legend). Antiviral therapy contin-
ued unabated until day 154 (see legend, Fig. 1A). Daily
administration of IL-2 (120,000 IU) by the subcutaneous
route was chosen and based on the pharmacokinetics of
IL-2 in macaques (our unpublished results) and began
on day 70 and ended on day 196. Four treatment-naive
rhesus macaques with long-standing SIVmac251 infec-
tion (11–15 months) received the same antiviral therapy
treatment and IL-2 at the same dose. Table 1 shows the
mean levels of SIV RNA in plasma, average CD4 T cell
numbers, and previous immunization schedule for these
four macaques.
Quantification of plasma SIV RNA
We quantified the level of SIVmac251 RNA in plasma
by nucleic acid sequence-based isothermal amplifica-
tion assay using SIVmac251-specific oligonucleotide
primers as described previously (Romano et al., 2000).
The limit of sensitivity of the assay was 2  103 copies
per 100 l of plasma.
Immunological assays
Mononuclear cells isolated from peripheral blood
were stained with anti-human CD3 antibody (FITC-la-
beled, clone SP34, Becton–Dickinson, San Jose, CA),
anti-human CD8* antibody (PerCP-labeled, Becton–Dick-
inson), and analyzed by flow cytometry assays as de-
scribed previously. To assess the frequency of SIV-spe-
cific CTL, we measured the number of CD8 T cells
stained with the Mamu-A*01-restricted SIV Gag181–189
CM9 tetramer-PE by flow cytometry (FACSCalibur, Bec-
ton–Dickinson).
DNA sequence analysis
We used end-point dilution DNA sequencing of plasma
viral RNA to screen for the presence of mutations in the
Mamu-A*01-restricted Gag181–189 CM9 epitope. Viral par-
ticles were isolated from plasma by centrifugation at
25,000 g for 1 h. The particles were lysed in a solution
containing 48% guanidine thiocyanate, 1.4% dithiothreitol,
1% N-laurolylsarcosine, and 1% sodium citrate. Viral RNA
was precipitated with 100% isopropanol and 70% ethanol
and then resuspended in 50 l of RNA diluent. The viral
RNA was amplified by PCR with SIV gag-F outer primer
(nucleotides 319 to 342: 5ACCTAGTGGTGGAAACAG-
GAACAG3) and SIV gag-R outer primer (nucleotides 930
to 903; 5TGTTTGTTCTGCTCTTAAGCTTTTGTAG3); SIV
gag-F inner primer (nucleotides 374 to 395; 5AGCAC-
CATCTAGTGGCAGAGGA3) and SIV gag-R inner primer
(nucleotides 883 to 863; 5GAAATGGCTCTTTTGGC-
CCTT3). The positions of the oligonucleotide primers
are numbered according to the gag gene of the SIV-
mac251 isolate. After extraction and amplification, the
PCR-product DNA inserted into vector pCRII by the prin-
ciples of T-A cloning (Invitrogen TOPO TA Cloning Kit)
and 8 to 13 inserts were sequenced and analyzed with a
sequencing system (Prism 377, Applied Biosystems, Fos-
ter City, CA) as described previously.
We used direct sequencing of plasma viral RNA to
assess the frequency of mutations coding for drug resis-
tance in the reverse transcriptase region of the SIV-
mac251 pol gene. Plasma viral RNA was amplified by
PCR with SIV pol-F outer primer (nucleotides 658 to 676;
5TAAAGCCAGGAAAGGATGG3) and SIV pol-R outer
primer (nucleotides 1365 to 1346; 5TGGCAACTC-
TATCTTTTGCA3); SIV pol-F inner primer (nucleotides
681 to 698; 5AAATTGAAGCAGTGGCCA3) and SIV pol-R
inner primer (nucleotides 1333 to 1316; 5TTGGCCA-
CAATTCGTACC3). The positions of the oligonucleotide
primers are numbered according to the pol gene of the
SIVmac251 isolate. The PCR-product DNA was se-
quenced directly and analyzed for mutations coding for
resistance to DDI (K45R, L74V, and M184V), d4T (M41L,
D67N, K70R, L210W), or PMPA (K65R) in the reverse
transcriptase region of the pol gene of SIVmac251 with a
sequencing system as described above.
The positions of the deduced amino acid substitutions
are numbered according to the reverse transcriptase
region in the pol gene of the SIVmac251 isolate. In
reconstruction experiments, this assay will discriminate
a genetic variant when represented in the virus popula-
tion at a frequency of more than 30%.
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